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Abstract: Tumors can undergo long periods of dormancy, with cancer cells entering a largely quiescent, non-
proliferative state before reactivation and outgrowth. For a patient, these post-remission tumors are often drug 
resistant and highly aggressive, resulting in poor prognosis. To understand the role of the extracellular matrix 
(ECM) in regulating tumor dormancy, we created an in vitro cell culture system that combines carefully 
controlled ECM substrates with nutrient deprivation to observe entrance into and exit from dormancy with live 
imaging. We saw that cell populations capable of surviving entrance into long-term dormancy were 
heterogeneous, containing quiescent, cell cycle arrested, and actively proliferating cells. Cell populations that 
endured extended periods of serum-deprivation-induced dormancy formed an organized, fibrillar fibronectin 
matrix via avb3 and a5b1 integrin adhesion, ROCK-generated tension, and TGFβ2 stimulation. We surmised that 
the fibronectin matrix was primarily a mediator of cell survival, not proliferation, during the serum-deprivation 
stress, bacause cancer cell outgrowth after dormancy required MMP-2-mediated fibronectin degradation. Given 
the difficulty of animal models in observing entrance and exit from dormancy in real-time, we propose this 
approach as a new, in vitro method to study factors important in regulating dormancy, and we used it here to 
elucidate a role for fibronectin deposition and MMP activation.  
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Introduction 
Even after apparently successful treatment, disseminated 
tumor cells (DTCs) can remain viable for many years, 
entering into a prolonged period of dormancy before 
eventual reactivation and outgrowth. The presence of 
these disseminated, largely quiescent tumor cells in the 
bone marrow is a predictive marker of increased 
metastatic risk and poor prognosis [1, 2]. It has long been 
hypothesized that DTCs must land in hospitable tissues to 
grow, and many cells that disseminate to secondary 
organs are incapable, at least initially, of colonizing and 
proliferating into an overt metastasis [3]. However, it is 
debated whether the extracellular matrix (ECM) of the 
secondary tissue site, or any tumor-cell associated 
remodeling of said ECM, is a primary determinant of the 
fate of disseminated tumor cells.  
 
Strong evidence is emerging to support that certain ECM 
proteins can promote cell dormancy, including 
thrombospondin 1 on the microvascular endothelium in 
breast cancer [4] and osteopontin within the bone marrow 
in leukemia [5]. In related examples, collagen I fibrosis is 
required for outgrowth of a dormant breast cancer 
population [6, 7], and collagen I-mediated signaling 
through DDR1 is required for reactivation of dormant 
breast cancer cells [8]. Physical properties of the ECM 
have been implicated as well, in that stiff environments 
promote cell proliferation, while softer surfaces support 
quiescence [9]. Related work has demonstrated that 
changes in the expression of ECM proteins can facilitate 
cell survival and outgrowth. For instance, fibronectin is 
produced by the stroma to support survival of 
metastasizing lung cancer cells [10]. Breast cancer cells 
have also been shown to trigger stromal periostin 
secretion [11] or produce their own tenascin C [12] to 
metastasize to the lung. Although not directly related to 
dormancy, these latter studies point to the importance of 
the generation of provisional matrices in first mediating 
survival, and then outgrowth of disseminated cells.  
 
Although entrance into dormancy and reactivation are 
continuous and dynamic processes, most dormancy 
studies use static, endpoint measurements in vivo. 
Because of the difficulty of live imaging in vivo and the 
prohibitive cost of high-resolution sampling in time, these 
studies inherently cannot simultaneously capture the 
spatial dynamics and heterogeneity of microenvironment 
components alongside the ability to visualize the 
proliferation or quiescence of an entire cell population. An 
endpoint measurement such as immunohistochemistry 
can identify co-localized Ki67-labeled cells with ECM [4, 
13], which correlates these proteins with proliferation. A 
major limitation with these studies is that there is no way 
to determine whether an individual Ki67-negative cell will 
eventually proliferate. Intravital imaging has started to 
address this problem, but it cannot yet view cells deep in 
the animal [5, 14-16], and it is nearly impossible to search 
an organ for an individual or small group of dormant cells. 
Despite these limitations, key recent in vivo studies have 
linked dormant cell outgrowth to fibrosis [6], TM4SF1 [8], 
miR-138 [17], and most recently laminin and smoking [14] 
in the lung. These efforts have required large pools of 
mice, particularly cost-prohibitive for most labs. We sought 
to find an alternative strategy that would enable higher 
throughput screens across cell sources and ECMs to 
determine how a population of disseminated cells enters 
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dormancy and eventually transitions to overt metastatic 
outgrowth.  
 
We developed a cell culture system capable of inducible 
and reversible population-level dormancy, where we can 
track the dynamics of individual cells and cell clusters. 
Using live imaging, we reveal significant heterogeneity 
across a dormant population of cells, simultaneously 
consisting of Ki67 -positive, -negative, senescent, and 
actively proliferating cells. Across a diverse set of human 
breast cancer cell lines, those that could enter long periods 
of dormancy consistently produced and assembled a 
fibronectin matrix through α5β1 integrin-mediated adhesion 
and ROCK-mediated cell tension. The ability to proliferate 
after dormancy depended on the ability to degrade the 
fibronectin matrix with MMP-2. We demonstrated that the 
recipient ECM determined successful entry into and exit 
from dormancy, providing clues toward new ECM-
associated therapeutic targets to prevent reactivation of 
dormant cell populations.  
 
 
Results 
 
In Vitro Model of Dormancy Reveals a Heterogeneous 
Population of Cell Cycle-Arrested and Proliferative 
Cells 
 
We combined our established system of defined ECM 
protein surfaces [18, 19] with serum-deprivation to force 
cell populations into a dormant-like state (Fig. 1a). We 
define population level, or tumor dormancy (herein 
referred to as “dormancy” [20]) as a cell population that is 
not increasing in number, but remains viable for an 
extended time (at least 4 and up to 12+ weeks). The cell 
culture medium was serum- and growth factor-free, but 
contained amino acids, vitamins, sugars, and salts. 
Continuous culture under this serum-deprivation condition 
decreased both cell number and number of actively cycling 
cells (Ki67+) cells over the first 10-14 days, and, 
importantly, we could rescue cell growth (both total 
number and Ki67+) by re-introducing serum (ZR-75-1 cells 
shown as typical example in Fig. 1a). This is indicative of 
a reversible, quiescent phenotype in some subpopulation 
of cells within the dormant culture.  
 
We performed a screen on 23 human breast cancer cell 
lines to find those capable surviving 8 weeks of serum 
deprivation (Fig. 1b), and our ability to rescue growth after 
7 days in serum or growth factor cocktails (Fig. 1c). Only 
8 cell lines had viable cells remaining after 8 weeks of 
serum starvation, and of those, only 5 cell lines could be 
re-stimulated to grow. For some of the poor performing cell 
lines (e.g. ZR-75-1), we could boost their serum-
deprivation survival by increasing the cell density (Fig. S1). 
We then asked if the ECM proteins presented on the cell 
culture surface affected this reversible dormancy by 
performing the assay on tissue culture plastic (TC), on a 
pure collagen 1 surface (Col), or on a mixture of proteins 
reflective of those found in the bone marrow (BM, a 
common site for clinical dormancy, Fig. 1b). Largely, the 
ability of the serum-deprivation stress to reduce cell 
culture confluency was independent of the ECM substrate, 
with few exceptions (most notably MDA-MB-468, BT549, 
MDA-MB-231). However, our ability to detect viable cells 
with a live-dead assay after a full 8 weeks of serum 
deprivation was highly substrate dependent for those 
cultures that did survive (Fig. 1b, right), with only the 
HCC1954 and Hs578T cell lines having viable cells left on 
all ECMs. 
 
From this panel, we chose to further investigate the 
HCC1954, BT549, and ZR-75-1 cell lines, as these cell 
lines represent different clinical subtypes (HER2+, triple 
negative, and luminal, respectively), and they exhibited 
high, moderate, and low survival under serum starvation, 
respectively. Serum-free culture over 4 weeks induced 
population-level dormancy in these cell lines, defined by 
few Ki67+ cells (Fig. 1d-e). When stimulated with serum, 
each cell population recovered their proliferation within a 
week. Interestingly, the HCC1954 cell line only fully 
recovered the Ki67+ cell population on a collagen I-coated 
coverslip, not on TCPS (Fig. 1e). To more deeply examine 
whether ECM was important in promoting survival in this 
assay, we screened serum-free survival of all three cell 
lines across several ECM proteins and protein 
combinations, varying amounts of those proteins, and 
different substrate stiffnesses. Of all these variables, we 
found that ECM protein identity, specifically collagen I, 
most significantly promoted cell survival during serum-
starvation (Fig. S2). For this reason, all subsequent 
experiments were performed using HCC1954 on this 
substrate unless otherwise noted. 
 
After 4 weeks of serum withdrawal, 10-20% of cells were 
still Ki67+, so we asked whether cells were actively 
proliferating, cell cycle arrested, or more homogeneously 
quiescent (Fig. 1d-e). First, we observed that a subset of 
cells expressed active p38 after 28 days of serum 
deprivation (Fig. 1f), characteristic of a well-characterized 
dormancy program in vivo [21]. Second, time-lapse 
imaging identified a small population of proliferating cells 
undergoing mitosis (Movie S1). Third, we found that 
expression of p21 was significantly elevated in our 
dormant population, indicative of cell cycle arrest (Fig. 
S3c). When we co-stained the population of cells after 2 
and 28 days of serum-deprivation for Ki67, p21, and 
senescence associated-β-galactosidase, we found most 
cells were Ki67+ after 2 days, but there was a richly 
diverse set of cell cycle states across the population after 
28 days (Fig. 1g). Most of the population was 
simultaneously p21+ and Ki67-, indicating that a large 
fraction of the surviving population was both cell cycle 
arrested and non-proliferative. However, importantly, cells 
remained that were negative for all markers, or were 
Ki67+, and we speculated that some of these cells were 
responsible for maintaining cell numbers after long periods 
of serum-deprivation and possibly responsible for re-
growth when serum was replenished in the “recovery” 
experiments. 
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To directly test whether individual cells could regain 
proliferation after dormancy, we sequentially labeled cells 
with BrdU at day 25 of serum-starvation, and EdU 
immediately upon serum-stimulated recovery, and 
followed them for either 3 or 7 additional days. We saw a 
large population of cells that not incorporate BrdU during 
serum deprivation, but did incorporate EdU during 
reactivation (Fig. 1h). Interestingly, when repeating this 
labeling experiment during sequential 72h periods of 
dormancy (i.e., label with BrdU during serum-starvation, 
then label with EdU during a second period of serum-
starvation), we identified small populations (~7%) that 
were positive for either BrdU or EdU, but not both (Fig. 1h, 
Serum 3 days), identifying small populations that were 
initially quiescent, then proliferative. Finally, the very small 
percentage of double positive cells decreased from day 3 
to 7, reflective of the cells slowly cycling during serum 
deprivation, and able to regrow after serum reintroduction. 
 
This method of serum deprivation-mediated dormancy 
allowed us to create a population of quiescent (Ki67-) 
cells, stable for 4-8 weeks (Fig. S3a). We wondered if 
these cells were a result of selection for cells that were 
robustly “dormancy-capable”. When we performed 
successive rounds of serum-removal and recovery on a 
single culture, we observed no change in the number of 
surviving or re-growing cells compared to a naïve 
population (Fig. S3b), suggesting that we recapitulated the 
heterogeneity of the original parental population upon re-
growth.  
 
Fibronectin Secretion and Organization is Required 
for Extended Dormancy 
 
We observed that many of the surviving cells had a 
spread, adherent phenotype, with some larger clusters of 
cells assembled into semi-adhered spheroids (Movie S1). 
This suggested to us that surviving dormant retained both 
strong cell-matrix and cell-cell adhesion. Since our initial 
screen identified ECM protein identity as a key factor in 
serum-free cell survival, we hypothesized that the dormant 
cell cultures may secrete ECM proteins to support survival. 
Figure 1. Serum withdrawal induces a reversible dormant phenotype in breast cancer cells. a) ZR-75-1 breast cancer cell line number and 
proliferation (Ki67 staining) over time with serum withdrawal (red) and recovery in full serum (blue). b) Survival of breast cell lines on TCPS (TC), 
collagen I coated coverslips (Col), or a mixture of ECM proteins inspired by those found in the bone marrow (BM)-coated coverslips. Average 
time to decrease confluence from 100% to 25% (scored by visual inspection by the same observer) is displayed on the left in red, and conditions 
where viable cells were detected at 8 weeks in culture are labeled on the right in black. c. Best performing cell lines were cultured on TCPS for 6 
weeks, and stimulated with varying media conditions (GF: growth factor cocktail, CM: conditioned medium from MSCs). Heat map shows increase 
in confluence over 7 days stimulation in blue. d. Ki67 quantification of BT549, and ZR-75-1 plated on TCPS and e. of HCC1954 on TCPS or 
collagen. Black: 10% serum control, blue: day 28 serum-free culture, green: 7 day recovery. f. Immunofluorescent staining for phospho-p38 (red; 
Thr180/Tyr182) and DAPI (blue) in HCC1954 on collagen coverslips after 2 and 28 days of serum-starvation (Scale bar 100 μm). g. Population 
quantification of HCC 1954 via co-staining of Ki67, p21, and senescence-associated b-galactosidase. h. BrdU and EdU labeling experiment 
schematic and results for HCC 1954 on collagen. Black: double negative, red: BrdU-positive, green: EdU-positive, blue: double BrdU- and EdU-
positive.. p < 0.05 was considered statistically significant. p < 0.05 is denoted with *, ≤ 0.01 with **, ≤ 0.001 with ***, and ≤ 0.0001 with ****. 	
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We performed LC-MS on HCC1954 samples enriched for 
ECM proteins at days 2 and 28 of serum-deprivation, and 
again after 1 week of recovery in full serum (Fig. S4a-b). 
We were excited to find many collagens, glycoproteins, 
and proteoglycans that were detectable at day 28, and 
subsequently disappeared when cell cultures were serum-
recovered (Fig. S4a-b).  
 
We were particularly interested in ECM proteins with 
known, strong roles in integrin-mediated adhesion, such 
as fibronectin, laminins, collagens, vitronectin, and 
osteopontin. Many of these were detected at day 28 of 
serum-free culture by LC-MS, and some of them were no 
longer detectable after recovery in serum (Figure S4b). 
When we looked more closely at these proteins via 
immunofluorescence, we saw that laminin (identified with 
a pan-laminin antibody), vitronectin, and osteopontin were 
all detected at increased levels during the dormant HCC 
1954 culture, but all appeared intracellular by visual 
inspection (Fig. 2a). Serum starved cells can uptake ECM 
to promote survival [22], potentially explaining the 
intracellular distribution of these proteins we observed. 
Only fibronectin appeared to be deposited at high amounts 
at the day 28 time point (Fig. 2a), and we observed this 
fibronectin secretion phenotype consistently across all 
three cell lines we tested (Fig. S5a). In particular, the 
HCC1954 cells organized a dense fibronectin matrix over 
28 days of dormancy, on both TCPS and collagen 
surfaces (Fig. S5b). They did not assemble fibronectin 
during 28 days of culture in serum-containing medium on 
any ECM, demonstrating that this secretion happens as a 
result of serum-starvation, not normal growth culture.  
 
When the cells were cultured in serum-free conditions and 
then these same cells were recovered in situ with 
complete serum for 7 days, the fibronectin matrix was 
locally degraded where we saw high densities of cells (Fig. 
2a, Fig. S6a). We hypothesized that cells were activating 
MMPs to degrade the fibronectin. Total MMP activity was 
measured with a fluorometric assay and MMP activity was 
high in cells under normal growth conditions, but 
undetectable in the dormant cell cultures (Fig. 2b). MMP 
activity was recovered with one week of recovery culture 
in serum, suggesting that MMPs were involved in the 
fibronectin degradation during reactivation. Specifically, 
zymography revealed that cathepsins S and V, and MMPs 
Figure 2. Dormant cells upregulate extracellular fibronectin specifically during serum withdrawal. a. Top rows, immunofluorescence for 
matrix proteins and DAPI in HCC 1954s on collagen in serum-free medium for 2 and 28 days. Bottom, immunofluorescence and for fibronectin in 
HCC 1954s grown for 28 days or serum starved for 28 days and recovered in situ for 1 week.  Scale: 100 μm. b. Total MMP activity of HCC 1954 
cells on collagen coverslips  c. Number of nuclei resulting from reactivation of dormant cells treated with a pan MMP inhibitor for 7 days (MMPi; 
GM6001, 25μm) or control (serum-containing media, no inhibitor). d. HCC 1954 day 7 survival on collagen, fibronectin (FN), or HCC 1954 day 28 
decellularized ECM (decell ECM) coverslips.  
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2 and 9 were low, but detectable, in normal growth 
conditions. These decrease during the serum-free culture 
(with the exception of MMP-2), and cathepsin V and MMPs 
2 and 9 were highly activated during growth recovery (Fig. 
S6b-c). Finally, when the cells were cultured the cells with 
a pan-MMP inhibitor (GM6001, 25 μM) during serum-
stimulated recovery, HCC 1954 re-growth was reduced 
during serum recovery (Fig. 2c), suggesting that MMP 
activation and fibronectin degradation is beneficial for 
regrowth after dormancy. Interestingly, inhibition of 
cathepsin activity with E64 (5 μm) did not inhibit 
reactivation and outgrowth, suggesting that outgrowth is 
MMP-, but not cathepsin-dependent (Fig S6d).  
 
To test whether the presence of a fibronectin-rich ECM 
directly supports long-term cell survival during serum-
deprivation, we allowed the dormant HCC1954 cultures to 
assemble the insoluble fibronectin matrices over the 28 
days of serum-deprivation, then we decellularized these 
samples, and reseeded new, naïve cell cultures onto 
them. When these cells were subjected to the long-term 
serum-deprivation on these decellularized, fibronectin-rich 
matrices, we found that HCC1954 and multiple other cell 
lines had significantly improved survival compared to the 
collagen surfaces across a several cell lines (Figs. 2d, 
S5c). This suggests that fibronectin promotes dormant cell 
survival during the serum starvation. However, some cell 
lines (AU565 and HCC1419) showed no ability to survive 
serum deprivation in the original screen, and also did not 
show improved survival with a decellularized ECM (Fig. 
S4c), so fibronectin is not sufficient to support entrance 
into dormancy by itself. We also surmised that the 
structure of fibronectin is important in this assay, because 
when we covalently coupled monomeric fibronectin to a 
coverslip, cells did not survive well (Fig. 2d). In fact, 
monomeric fibronectin did not support survival as well as 
collagen (Fig. 2d and S5d).  
 
Dormant Cells Assemble Fibronectin via Cancer-Cell 
Secreted TGFβ  
Because matrix assembly is classically stimulated by 
TGFβ signaling, we explored whether TGFβ signaling 
affected the survival of dormant cells. When we provided 
cell cultures with exogenous TGFβ1 (1 ng/ml) or TGFβ2 (2 
ng/ml) at every regular medium change, we saw no effect 
on cell survival at day 7 (Fig. 3a). Similarly, inhibition of 
TGFβ receptor signaling with LY-364947, a selective and 
ATP-competitive inhibitor of TGFβRI, did not affect day 7 
survival (Fig. 3a). When the dormant cell cultures were 
exposed to the inhibitor over 28 days, however, cell 
survival was significantly decreased, and we observed a 
marked decrease in the fibronectin matrix (Fig. 3b-c). 
Continuous treatment of the cultures with exogenous 
TGFβ1 or TGFβ2 for the entire 28-day serum-deprivation 
culture either increased or maintained survival, 
respectively (Fig. 3b-c). Analysis of the culture 
supernatant demonstrated that HCC 1954 express 
undetectable levels of TGFβ1 and TGFβ3 (Fig. 3d), but 
high levels of TGFβ2 at day 28 of serum-free culture, 
suggesting that serum-starvation stimulates TGFβ2 
secretion, which initiates fibronectin matrix remodeling 
and the survival of dormant cultures. 
 
Fibronectin is assembled via α5β1 integrin-mediated 
tension, and mediates survival via adhesion through 
αvβ3 and α5β1 integrins 
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Figure 3. TGFβ stimulates fibronectin matrix production that mediates survival during mitogen withdrawal. a, b. Survival 
of HCC1954 under control, TGFβ receptor inhibition (LY-364947, 5 uM) and TGFβ1 (1 ng/ml) or TGFβ2 (2 ng/ml) stimulation 
over a. 7 days or b. 28 days. c. Immunofluorescence for fibronectin (green) and DAPI (blue) at day 28. d. Expression of secreted 
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with ***, and ≤ 0.0001 with ****.  
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Fibronectin assembly occurs via adhesion through α5β1 
integrin and downstream RhoA activation, which then 
activates rho kinase (ROCK), generating tension to 
expose cryptic self-assembly sites in fibronectin, inducing 
polymerization [23-26]. The αvβ3 and α5β1 integrin 
heterodimers bind to fibronectin with high affinity, and we 
observed these subunits were transcriptionally 
upregulated in our fibronectin-producing dormant cells 
(Fig. S7). We tested whether this pathway of fibronectin 
assembly was important for dormancy phenotype by 
inhibiting ROCK (Y-27632). We administered Y-27632 to 
cell cultures during serum deprivation during the first 7 
days (entrance into dormancy), or continuously over all 28 
days (long-term dormant survival), or, finally, we allowed 
the dormant cells to build up a fibronectin matrix for the 
first 21 days of dormancy, and added the inhibitors during 
days 21-28 (Fig. 4a).  
 
The maximum dose of Y-27632 (10 μM) inhibited survival 
of cells over the first 7 days of serum-free culture on 
collagen-coated coverslips (Fig. 4b, dark blue bars). This 
maximum dose also inhibited cell survival when we 
administered the inhibitor after cells were allowed to pre-
establish the fibronectin matrix (Fig. 4b-c), and when we 
seeded cells onto a decellularized ECM (Fig. 4d). 
However, 10- and 100-fold lower doses of Y-27632 did not 
affect survival during the first 7 days, but prevented 
survival of cells when administered over the full 28 days of 
serum deprivation (Fig. 4e). When we supplemented the 
culture with 10 μg/ml of soluble fibronectin to potentially 
jump-start the matrix, this promoted survival over the 28 
days of serum-free culture, even in the presence of Y-
27632 (Fig 4g-h). This suggests that cells use ROCK to 
secrete and assemble fibronectin to survive serum-
deprivation culture. Maximum doses of ROCK inhibitor 
prevented cell survival in all cases, but these lower doses 
allowed us to observe the more specific role of ROCK in 
fibronectin assembly and long-term survival. 
 
Inhibiting α5 integrin did not affect survival on collagen over 
the first 7 days (Fig. 4b, green bar), but it reduced cell 
survival when dosed after establishment of the fibronectin 
matrix (from day 21-28, Fig. 4c). When we seeded cells 
onto a decellularized matrix while inhibiting α5 integrin, we 
saw no change in survival over the first 7 days (Figure 4d). 
Finally, inhibiting α5 integrin function during the entire 28-
day duration of the experiment inhibited cell survival under 
serum deprivation (Fig. 4e). We also saw an absence of 
fibronectin staining at day 28 in all these inhibitors 
conditions (Fig. 4f). Collectively, these results suggest that 
cells require α5 integrin to create the organized fibronectin 
matrices during serum deprivation. 
 
When β1 integrin, which dimerizes with many alpha 
subunits (including α5), was similarly blocked there was 
minimal ability for cells to survive during serum-starvation, 
regardless of when we applied the treatment (including 
seeding cells onto decellularized matrices (Fig. 5b-d)).  
This demonstrates that β1 integrin was driving adhesion to 
both the collagen and fibronectin matrices. To more 
specifically target adhesion to fibronectin, we used 
cilengitide, a cyclic RGD drug that reduces fibronectin 
binding primarily via αvβ3 and αvβ5 integrins [27]. 
Cilengitide treatment did not affect the number of cells 
adhered to the collagen coverslip (Fig. 5b), but it was 
highly effective at disrupting survival when the dormant 
cells had assembled a fibronectin matrix (Fig. 5c), and 
when cells were seeded onto a decellularized matrices 
containing dense fibronectin (Fig. 5d). Although there is 
some evidence that αvβ3 integrin can bind to denatured 
collagen [28], in our cells, cilengitide appeared to reduce 
adhesion to fibronectin but not to collagen-coupled 
coverslips.  
 
We performed a small screen of tyrosine kinases to 
identify pathways activated during adhesion to the 
decellularized fibronectin matrices. Across this screen, 
only ERK was highly phosphorylated in both the dormant 
cell cultures and during adhesion to the decellularized 
ECMs (Fig. S8a-e). Pharmacological inhibitors to FAK, 
MEK and ERK all decreased cell survival over the first 7 
days of serum starvation on both the collagen- and 
fibronectin-coupled coverslips and decellularized ECMs 
(Fig. 5b-d). This supports a hypothesis that cells are 
activating a survival pathway driven by αvβ3 integrin 
mediated-adhesion to the assembled fibronectin matrix, 
downstream of ERK pathway activation during this serum-
starvation induced dormancy in culture.  
 
Discussion 
Applied cellular stresses, such as serum deprivation, 
application of drug, or hypoxia, have been used to select 
for cell populations primed for migration and metastasis 
[29-33]. By combining this approach with engineered 
materials, we selected for human breast cancer cell lines 
that can enter and survive dormancy based on their ability 
to secrete and organize ECM, a phenotype likely missed 
using traditional culture platforms or genetic profiling alone 
[34]. Our data supports the idea that dense fibronectin 
matrices facilitate long-term survival of cancer cells during 
serum deprivation-induced dormancy. Inhibiting α5β1, 
ROCK, or TGFβ receptor signaling prohibited fibronectin 
assembly, eliminating a large population of the surviving 
dormant cells. We suggest a role for α5β1 in this process, 
as adhesion to fibronectin through α5β1 integrin is 
associated with mature focal adhesions [23] to support 
intracellular tension, while adhesion through αvβ3 does so 
weakly [35]. Reactivation and outgrowth of the cancer cells 
after the dormancy period could be inhibited by blocking 
their ability to degrade the fibronectin matrix via MMPs. 
Although they target different aspects of fibronectin matrix 
dynamics, both approaches could be promising 
mechanisms to eliminate dormant cell populations.  
 
Other in vitro models have been used to study 
spontaneous dormancy [36, 37]; using far shorter culture 
times than our method here. Other approaches have used 
cell lines pre-selected with distinct proliferative or dormant 
potentials (e.g., the 4T1 and D2 series) [7, 17, 38-41]. Our 
study is unique in that a proliferative, heterogeneous cell 
population can be induced to become dormant via serum-
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deprivation stress, and the dormancy-competent cells can 
be subsequently reactivated. This approach is analogous 
to that used in the drug resistance studies, where resistant 
cells are selected via prolonged drug-induced stress [42, 
43]. As one validation of our approach, the HCC 1954 cell 
line capable of showing this dormancy phenotype was also 
identified by Massagué and colleagues as one of two cell 
lines capable of generating dormancy-competent cells in 
vivo [13].  
 
It has been proposed that dormant micrometastases are a 
mixture of arrested, quiescent, and slow cycling cells [44]. 
This has not been completely clarified since these studies 
were endpoint analyses, relying on defining dormant cells 
by fixed staining for lack of proliferation (Ki67-), DNA 
Figure 4. Dormancy-associated fibronectin is assembled via a5b1 integrin and ROCK to mediate survival. a. Experimental 
timeline of inhibitor dosing. Day 7 experiments were dosed continually through a day 7 endpoint; Day 28 experiments were dosed 
continually through a day 28 endpoint; separate cultures were established for 21 days, where inhibitor dosing was initiated for an 
additional 7 days (‘dose established culture’). b. Day 7 survival of HCC 1954 on collagen with inhibitors dosed at seeding and every 
medium change. c. Survival of cells with inhibitors, dosed after establishment of dormant culture for 21 days, and then subsequent 
dosing at every medium change through days 21-28. d. Day 7 survival of HCC 1954 on decellularized matrix with inhibitors dosed 
at every medium change. e. Day 28 survival of cells with inhibitors dosed at seeding and every medium change throughout the 
entirety of the experiment. Green: a5 integrin function affecting antibody; blues: Y-27632 (ROCK inhibitor at various concentrations). 
f. Immunofluorescence for fibronectin (green) and DAPI (blue) at day 28 on collagen with inhibitors dosed for the entire 28-day time 
period. Scale: 100 µm. g. Immunofluorescence for fibronectin (green) and DAPI (blue) at day 28 on collagen with exogenous 
fibronectin (10 µg/mL), or fibronectin with Y-27632 (1 µm). h. Day 28 survival of cells under control, exogenous fibronectin, or 
fibronectin with Y-27632. p < 0.05 is denoted with *, ≤ 0.01 with **, ≤ 0.001 with ***, and ≤ 0.0001 with ****.  	
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synthesis (EdU incorporation), or cell cycle stalling (p27+) 
[4, 21, 38]. These studies report that 70-80% of Ki67- or 
p27+ are dormant in vivo [4, 21]; however, in our culture 
system, the remaining 20-30% of Ki67+ cells could be cell 
cycle arrested (p21+) or proliferative (Figure 1g). By 
imaging live cells during the dormant culture, we revealed 
the presence of persisting cycling cells, quiescent cells, 
and arrested cells, a population-wide phenotype 
reminiscent of tumor dormancy. 
 
We were initially surprised that our data appeared to 
contradict that of Aguirre-Ghiso, who has very thoroughly 
characterized an α5β1 integrin/EGFR/uPAR/fibronectin 
mechanism, mediating proliferation through ERK, not p38 
[45, 46]. His lab showed that fibronectin fibrils block the 
p38 activity characteristic of quiescent cells, which results 
in sustained ERK signaling and proliferation [45, 47, 48]. 
Our data showed that dormant cells simultaneously 
suppressed p38 and activated ERK (Fig. S6a-b). 
However, when looking closer, immunofluorescence 
revealed that high phospho-ERK was ubiquitous (Fig. 
S6E), but phospho-p38 was heterogeneous (Fig. 1f). This 
suggests that this subpopulation of dormant cells may be 
activating the same stress signaling pathway described by 
the Aguirre-Ghiso lab [47]. In fibroblasts, serum withdrawal 
induces a reversible quiescence [49], which initially have 
decreased ERK activity that is eventually regained and 
sustained. This report is consistent with the high phospho-
ERK we report at long dormancy times in cancer cells (Fig. 
S6a). Induction of stromal cell senescence is associated 
with acute activation of p38 and IL-6 release after 
genotoxic stress in lymphoma [50]. Therefore, it’s possible 
that the heterogeneous population of p38-high and –low 
cells is associated with senescent and quiescent cells, 
respectively, allowing for a population-level dormancy in 
response to serum-deprivation stress. 
 
We found that the assembly of fibronectin coincided with 
entrance into a dormant phenotype, and this fibronectin 
assembly was dependent on TGFβ. Similarly, in cancer 
associated fibroblasts (CAFs), TGFβ is required to create 
a desmoplastic ECM [51]. We observed that cells required 
ROCK activation to assemble this fibronectin matrix, and 
other work has shown that there may be a feedback loop 
between tension-mediated TGFβ release and matrix 
assembly [52]. Cells responding to TGFβ are less 
proliferative, but more invasive and drug resistant [53]. 
Further, there are other reports of a TGFβ2 regulating the 
dormancy of tumor cells [21, 54]. The well-characterized 
senescence-associated secretory phenotype (SASP) is 
associated with a secretome that includes TGFβ [55]. This 
suggests that the senescent subpopulation we observed 
in our cultures (Fig. 1g) may be contributing to TGFβ 
release and subsequent fibronectin deposition. TGFβ is a 
promising target in many cancer clinical trials, and we 
suggest here a role for an anti-TGFβ therapy to prevent 
survival of dormant disseminated cells [56]. 
 
Our data suggests that targeting the TGFβ-mediated 
secretion of fibronectin allows cells to maintain a dormant 
Figure 5. Survival is mediated via adhesion-FAK-ERK signaling. a. Experimental timeline of inhibitor dosing. Day 7 experiments 
were dosed continually through a day 7 endpoint; Day 28 experiments were dosed continually through a day 28 endpoint; separate 
cultures were established for 21 days, where inhibitor dosing was initiated for an additional 7 days (‘dose established culture’). b. HCC 
1954 survival at day 7 on collagen coverslips with selected inhibitors dosed for the duration of the experiment. c. Survival of HCC 
1954 cells after establishment of dormant culture for 21 days, and then subsequent dosing with inhibitors through days 21-28. d. 
HCC1954 survival at day 7 with inhibitors when seeded onto HCC 1954 decellularized ECM. Black: control, blue: anti-b1 (MAB17781, 
1 µg/ml), green: FAK inhibitor 14 (10 µM), purple: PD0325901 (MEK inhibitor, 10 µM), red: FR180204 (ERK inhibitor 20µM), gray: 
cilengitide (100 µM). p < 0.05 is denoted with *, ≤ 0.01 with **, ≤ 0.001 with ***, and ≤ 0.0001 with ****.  	
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state, agreeing with a recent demonstration that the 
optimal anti-TGFβ treatment for metastasis was during the 
pre-metastatic stage [57], although this is clinically 
challenging, because metastatic cells can disseminate 
extremely early during disease progression [58]. In our 
work, fibronectin disassembly occurred during the 
transition to outgrowth, and preventing MMP-mediated 
degradation of fibronectin may provide a better strategy to 
maintain dormancy and prevent reactivation. Together, 
this suggests that the dynamic control of fibronectin 
secretion/assembly and degradation may be a 
prerequisite for metastasis via promoting survival and 
subsequent outgrowth of dormant disseminated cells. 
Fibronectin expression, assembly, and degradation have 
all been featured as critical components of drug resistance 
and metastasis: MAPK and BRAF inhibitors can promote 
fibronectin production to promote drug resistance [59, 60]; 
serum starvation induces ECM secretion [61]; and hypoxia 
stimulates matrix remodeling and ensuing drug resistance 
[62]. Fibronectin, specifically, prevents serum deprivation-
induced apoptosis via MEK1 and ERK activation [63], 
promotes proliferation [64], and permits survival of growth 
arrested cells through α5β1 integrin [65, 66], all in 
agreement with our findings.  
 
We uncovered a mechanism by which dynamic fibronectin 
assembly and disassembly regulate breast cancer cell 
dormancy, which could be targeted to eliminate dormant 
cells or prevent their reactivation. Treatment regimens for 
eliminating dormant cells are difficult due to the stochastic 
nature of reactivation, and the extremely long time before 
relapse [67]; however, several treatment regimens have 
been proposed [67-70]. One camp argues that since these 
dormant cells are difficult to find and treat, they could be 
reactivated and sensitized to chemotherapy. This 
approach obviously comes with risk, as a patient would 
have awakened dormant cells that could be drug resistant. 
Another camp promotes a regimen that would keep cells 
in a dormant state, but this could be costly, lengthy, and 
unnecessary if a patient does not have micrometastases. 
A more exciting possibility is the recent revelation that 
dormant cells may in fact be sensitized to chemotherapy 
in an ECM-dependent manner [5, 71]. This agrees with our 
suggestion that targeting survival signaling from cell-ECM 
adhesion could be a valuable treatment option. There is 
promising preclinical evidence of efficacy of cilengitide as 
an anti-metastatic drug [72-74], and co-targeting dormant 
cells with cilengitide and chemotherapy may prevent 
metastatic outgrowth by eliminating dormant cells at the 
minimal residual disease stage.  
 
Materials and Methods 
Breast cancer cell culture  
All cells were cultured at 37°C and with 5% CO2, unless 
otherwise noted. All cell culture supplies were purchased 
from Thermo Fisher Scientific (Waltham, MA). AU565, 
BT474, HCC 1395, HCC 1419, HCC 1428, HCC 1806, 
HCC 1954, HCC 202, HCC 38, HCC 70, ZR-75-1 were 
cultured in RPMI supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin (P/S). BT549, 
Hs578T, MCF7, MDA-MB-231, MDA-MB-468, MDA-MB-
231 BoM (bone tropic), MDA-MB-231 BrM2a (brain tropic), 
MDA-MB-231 LM2 (lung tropic), SkBr3 were cultured in 
DMEM with 10% FBS, 1% P/S. MDA-MB-175 was cultured 
in Leibovitz’s L-15 medium with 10% FBS and 1% P/S 
without supplemental CO2, and MDA-MB-134 and MDA-
MB-361 were cultured in Leibovitz’s L-15 medium with 
20% FBS and 1% P/S without supplemental CO2. Tropic 
variants were a kind gift from Joan Massagué [75-77]; 
MDA-MB-231 were provided by Sallie Smith-Schneider; 
BT549, MCF7, and SkBr3 were provided by Shannon 
Hughes; and all others were provided by Mario Niepel.  
 
Biomaterial Preparation  
Glass coverslips (5, 15, and 18mm) and PEG-PC 
hydrogels were prepared as previously described [18, 19]. 
Briefly, coverslips (Thermo Fisher Scientific) were UV-
ozone treated and silanized through vapor phase 
deposition of (3-aminopropyl)triethoxysilane (Sigma-
Aldrich) at 90 °C for a minimum of 18 hours. The coverslips 
were rinsed sequentially in toluene (Fisher Scientific), 95% 
ethanol (Pharmco-AAPER, Brookfield, CT), and water, 
and dried at 90 °C for one hour. They were then 
functionalized with 10 g/L N,N-disuccinimidyl carbonate 
(Sigma-Aldrich) and 5% v/v diisopropylethylamine (Sigma-
Aldrich) in acetone (Thermo Fisher Scientific) at room 
temperature for two hours. Coverslips were rinsed three 
times in acetone and air-dried. ECM proteins (collagen I 
and natural mouse laminin were purchased from Life 
Technologies, human plasma fibronectin from Millipore, 
human collagen IV from Sigma-Aldrich, recombinant 
human tenascin C, osteopontin, thrombospondin-1, and 
vitronectin from R&D Systems, and laminin 511 and 
laminin 521 from Biolamina) were covalently bound to the 
glass surface by incubation at room temperature for three 
hours, then with 10 mg/cm2 MA(PEG)24 (Thermo Fisher 
Scientific) for two hours to block non-specific protein 
adsorption, rinsed three times in PBS, and UV-sterilized 
prior to cell seeding. Functionalized coverslips were 
placed into tissue culture plates that were coated with 100 
μg/cm2 polyHEMA block non-specific cell adhesion.  
For experiments on tissue culture polystyrene plates 
(TCPS), TCPS wells were coated with serum-containing 
medium at 37°C for at least 1 h prior to cell seeding to 
facilitate cell adhesion. ECM proteins were used at 2 
 g/cm2 unless otherwise noted. The Protein Atlas [78] was 
used to determine the composition of integrin-binding 
ECM proteins in human bone marrow, which primarily 
includes collagens, fibronectin, and laminins [79]. We 
created a minimalist representation of bone marrow ECM 
that contains proteins known to bind to cancer cells [18], 
composed of 50% collagen I, 15% laminin 521, 12% 
fibronectin, 8% tenascin C, 8% osteopontin, 5% laminin 
511, and 2% vitronectin by weight. Collagen I and natural 
mouse laminin were purchased from Thermo Fisher 
Scientific (Carlsbad, CA), human plasma fibronectin from 
Millipore (Billerica, MA), human Collagen IV from Sigma-
Aldrich (St. Louis, MO), recombinant human Tenascin C, 
osteopontin, thrombospondin-1, and vitronectin from R&D 
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Systems (Minneapolis, MN), and Laminin 511 and Laminin 
521 from Biolamina (Matawan, NJ).  
 
Establishment of Dormant Cell Cultures 
Breast cancer cells were seeded onto biomaterials in 
serum-free medium using the specified culture medium for 
each cell line For seven-day experiments on different ECM 
proteins, protein concentrations, and hydrogels in Figs. 1a 
and S1, cells were seeded at 11,000 cells/cm2. For all 
other experiments, cells were seeded at 47,000 cells/cm2 
to extend the possible duration. Serum-free medium was 
changed every 2-3 days for the duration of the experiment. 
At specified time points, cells were changed to serum-
containing medium to grow a recovered population. 
Recovery was assessed after seven days of growth. 
 
In cases where pharmacological inhibitors were used, 
inhibitor was replenished with every regular medium 
change. Concentrations of inhibitors and antibodies were 
chosen empirically to not affect initial seeding density. 
Where noted, inhibitors or antibodies were included in the 
serum-free or serum-containing medium at the following 
concentrations: E64, Tocris, 5 μm; ERK inhibitor 
FR180204, Sigma-Aldrich, 20 μm, FAK inhibitor 14, 
Sigma-Aldrich, 10 μm; soluble fibronectin, Millipore, 10 
μ/ml; anti-α5 AF1864, R&D Systems, 1 μg/ml; cilengitide, 
Apex Biotechnology, 100 μM, anti-β1 MAB17781, R&D 
Systems, 1 μg/ml; MEK inhibitor PD0325901, Sigma-
Aldrich, 10 μM; pan-MMP inhibitor GM6001, Millipore, 25 
μM; ROCK inhibitor Y-27632, Millipore, 0.1, 1, 10 μM; pan-
TGFβ AB-100-NA, R&D Systems, 20 μg/ml; anti-TGFBR1, 
LY-364947, Sigma-Aldrich, 5 μM).  
 
Where noted in specific experiments, medium was 
supplemented with 1 ng/ml EGF (R&D Systems, 
Minneapolis, MN), 100 ng/ml FGF1 (R&D Systems), 100 
ng/ml IGF1 (R&D Systems), 100 ng/ml HGF (R&D 
Systems), 1 ng/ml TGFβ1 (Sigma-Aldrich, St. Louis, MO), 
100 ng/ml SDF1α (R&D Systems), or conditioned medium 
collected from mesenchymal stem cells to stimulate 
reactivation and growth. Where noted, medium was 
supplemented with a growth factor cocktail for recovery 
(100 ng/ml EGF (R&D Systems), 100 ng/ml FGF1 (R&D 
Systems), 100 ng/ml TGFβ1 (R&D Systems). In addition, 
2 ng/ml TGFβ2 (Sigma-Aldrich) or 1 ng/ml TGFβ1 (Sigma-
Aldrich) was supplemented in serum free medium.  
 
Characterization and Viability of Dormant Cell Cultures 
Viability was assessed after 8 weeks of culture by staining 
with 4 μM ethidium homodimer-1 and 2 μM calcein AM 
(Thermo Fisher Scientific). Any condition where at least 
one viable cell was identified was considered positive for 
the presence of viable cells. Proliferation was assessed 
with immunofluorescence for Ki67, G1/S arrest by 
immunofluorescence for p21, and senescence by 
senescence-associated β-galactosidase (SA-β-gal) 
staining (Sigma-Aldrich). Immunofluorescence was 
performed according to standard protocols, and imaging 
was performed using a Zeiss Axio Observer Z1 with color 
and monochrome cameras or a Zeiss Spinning Disc Cell 
Observer SD (Zeiss, Oberkochen, Germany). The 
following primary antibodies were used for 
immunofluorescence: BrdU, ab8039, Abcam, 2 μg/ml; 
collagen I, ab6308, Abcam, 1:200; EdU, Click-iT EdU, Life 
Technologies, per manufacturer’s protocol; phosphor 
Trh202/Tyr204 ERK, #4370, Cell Signaling, 1:200; 
Fibronectin #563100, BD Biosciences, 1:200; Ki67, 
ab16667, Abcam, 1:200; pan-laminin, ab11575, Abcam, 
1:100; osteopontin, ab8448, Abcam, 1:1000; phosphor 
Thr180-Tyr182 p38, #4511, Cell Signaling, 1:800; p21, 
ab7093, Abcam, 1:100; vitronectin, ab13413, Abcam, 1 
μg/ml. 
 
BrdU and EdU Incorporation and Staining 
10 μM BrdU (Thermo Fisher Scientific) was dosed for 3 
days in serum free medium for 72 h prior to the day 28 
endpoint. At day 28, the BrdU containing medium was 
removed, cells were washed once in serum free medium, 
and then stimulated with serum-containing or serum-free 
medium containing 10 μM EdU (Thermo Fisher Scientific). 
Cells were fixed after an additional 72 h or 7 days of 
culture, with regular medium changes. Cells were 
permeabilized in TBS-T, and DNA was denatured with 1M 
HCl (10 min, on ice), 2M HCL (10 min, RT), and 
phosphate-citric acid buffer (10 min, RT). Then, staining 
for EdU was performed according to the manufacturer’s 
protocol (Life Technologies), and, subsequently BrdU 
staining was performed using antibody labeling (Abcam, 
ab8039, 2 μg/ml).  
 
Decellularized ECMs 
Decellularized ECMs were generated from dormant HCC 
1954 cells cultures (originally seeded on collagen I-
functionalized glass coverslips at 47,000 cells/cm2 in 
serum-free culture for 28 days) were according to a 
published protocol  [80]. Briefly, cells were extracted with 
warm PBS containing 0.5% Triton X-100 (Thermo Fisher 
Scientific) and 20 mM NH4OH (Thermo Fisher Scientific), 
added drop-wise, and incubated at 37 °C for 10 minutes. 
Twice the volume PBS was then added, matrices stored 
at 4 °C overnight, and washed carefully with PBS 3 times. 
Decellularized ECMs were created and stored hydrated at 
4 °C for up to 1 month prior to use. Decellularized ECMs 
were transferred to new well plates and rinsed once each 
in PBS and serum-free medium prior to use.  
 
Statistical Analysis 
Statistical analysis was performed using Prism v6.0b. Data 
are reported as mean ± standard error. Statistical 
significance was evaluated using a one-way analysis of 
variance, followed by a Tukey’s post-test for pairwise 
comparisons. For Kaplan-Meier survival analysis, 
significance was determined using a Log-rank (Mantel-
Cox) test. p < 0.05 is denoted with *, ≤ 0.01 with **, ≤ 0.001 
with ***, and ≤ 0.0001 with ****; p ≥ 0.05 is considered not 
significant (‘ns’).  
 
Additional methods are described in the Supplemental 
Information, including antibodies for immunofluorescence 
and small molecule and antibody inhibitors or activators.  
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